This site is intended for UK healthcare professionals

 

Sponsored

Sponsored

Studies report up to 18% (n/N = 9/49) of patients aged ≥60 years old with heart failure with preserved ejection fraction (HFpEF) had transthyretin amyloid cardiomyopathy (ATTR-CM), one of the main types of cardiac amyloidosis.1 Clinical expert Dr Kate Gatenby highlights this and gives an overview of the causes, diagnosis and best practices in the management of patients with ATTR-CM.

Promotional video developed and funded by Pfizer Ltd intended for UK HCPs only.

PP-VYN-GBR-2016 | March 2026

Sponsored

Dr Rajiv Sankaranarayanan, Consultant Cardiologist, University Hospitals Liverpool is joined by Dr Parin Shah, Consultant Cardiologist, Swansea Bay University Health Board and Matthew Sunter, Lead Heart Failure Nurse, St. George's University Hospital, London as they share how they’ve implemented and adapted the STRONG-HF1 pathway to improve heart failure care. They discuss early patient identification, rapid optimisation, and collaborative follow-up models tailored to local needs. Through shared learning and teamwork across disciplines, each centre has refined its approach to deliver more efficient, patient-centred heart failure management.

MC-UK-01533 | December 2025

This webinar has been sponsored by A Menarini Pharmaceuticals Ireland and A. Menarini Farmaceutica Internazionale SRL who have had no input into the topics discussed or selection of speakers.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.